Sells fast-moving consumer healthcare brands in India across three therapeutic areas: allergy (Allegra, Avil), pain (Combiflam), and vitamins/minerals/supplements (DePURA). The company was carved out of Sanofi's prescription pharma business and is positioning itself as a brand-equity-driven OTC player under global parent Opella, whose other shareholder is CD&R. Domestic sales contribute the bulk of revenue, with a smaller export book that fell 9% in Q2 FY26 on a high base; total Q2 FY26 revenue was Rs 2,357 mn (+7% YoY) and H1 FY26 revenue was Rs 4,649 mn (+18% YoY). Brands hold top-five positions in their categories—Avil is #1 by volume, Allegra #3 by value, Combiflam #5, and DePURA top-5 in Vitamin D. Distribution is being deepened via direct retail coverage, with the company planning to roughly 2X its direct retail footprint and add 50,000 healthcare professionals via digital in 2026. Production is almost entirely local, and the model is shifting from prescription-style doctor dependence toward consumer self-choice, supported by doctor recommendations and consumer education. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Allergy brands, Pain brands, Vitamins, minerals and supplements (VMS), Domestic sales, Export sales. Brand-equity-driven fast-moving consumer healthcare (FMCH) in allergy, pain and VMS; recently demerged from Sanofi's prescription pharma business and repositioned around consumer self-choice rather than prescription pulls.
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | — | — |
| EBITDA (ex other income) | — | — |
| margin % | — | — |
| Owners' profit | — | — |
| EPS, as reported (₹) | — | — |
| ROE % · ROCE % | — · — | — · — |
| Debt / equity (x) | — | — |
| Cash from operations | — | — |
| Capex | — | — |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 |
| Profit before tax | 61 | 63 | 67 | 79 | 84 | 91 | 91 | 92 |
| Net profit | 45 | 44 | 50 | 61 | 63 | 67 | 68 | 69 |
| EPS (₹) | 19.54 | 19.25 | 21.69 | 26.36 | 27.31 | 28.87 | 29.44 | 29.87 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 30 Jul 2026 · Sanofi Consumer Healthcare submits Q1 FY27 results newspaper clippings to exchanges | compliance | minimal | — | — |
| 28 Jul 2026 · Sanofi Consumer Healthcare Q2 FY26: Revenue up 7%, PBT up 16% YoY | results | high | — | — |
| 28 Jul 2026 · Sanofi Consumer Healthcare Q2 FY26: PAT rises 13 percent YoY to Rs 688 mn | results | high | — | — |
| 28 Jul 2026 · Q2 FY26: Revenue up 7% to ₹2,357M, PBT grows 16% YoY on domestic recovery | results | high | — | — |
| 22 Jul 2026 · Board meeting on 28 Jul to approve Q1 FY27 unaudited results | results | low | — | — |
| 9 Jul 2026 · Routine compliance filing: RTA certificate for Q1 under SEBI Regulation 74(5) | compliance | minimal | — | — |
| 9 Jul 2026 · Routine SEBI Regulation 74(5) certificate filing for Q1 FY26-27 | compliance | minimal | — | — |
| 29 Jun 2026 · Auditor change: PwC appointed, Kalyaniwalla & Mistry resigned | management changes | medium | — | — |
| 29 Jun 2026 · AGM results: Rs. 75 dividend declared, all 6 resolutions passed | board shareholder meetings | medium | — | — |
| 26 Jun 2026 · 3rd AGM held on June 26, 2026; Rs 75 per share final dividend declared | board shareholder meetings | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 34.8 | 28.9 | 96 of 169 | 44% |
| P/B | 26.6 | 3.3 | 163 of 163 | 0% |
| ROCE | 48.1 | 10.8 | 6 of 183 | 97% |
| ROE | 39.3 | 10.4 | 10 of 171 | 95% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 40.6 | 17.5 | 8 of 165 | 96% |
| Revenue growth | 6.7 | 16.3 | 106 of 161 | 34% |
| Profit growth | 13.3 | 30.9 | 99 of 158 | 38% |
| Market cap | 9246 | 839 | 45 of 182 | 76% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
